{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T06:06:53Z","timestamp":1772172413863,"version":"3.50.1"},"update-to":[{"DOI":"10.1371\/journal.pcbi.1007218","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2020,2,6]],"date-time":"2020-02-06T00:00:00Z","timestamp":1580947200000}}],"reference-count":54,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2020,1,27]],"date-time":"2020-01-27T00:00:00Z","timestamp":1580083200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000266","name":"Engineering and Physical Sciences Research Council","doi-asserted-by":"publisher","award":["EP\/L015374\/1"],"award-info":[{"award-number":["EP\/L015374\/1"]}],"id":[{"id":"10.13039\/501100000266","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.ploscompbiol.org"],"crossmark-restriction":false},"short-container-title":["PLoS Comput Biol"],"DOI":"10.1371\/journal.pcbi.1007218","type":"journal-article","created":{"date-parts":[[2020,1,27]],"date-time":"2020-01-27T13:36:35Z","timestamp":1580132195000},"page":"e1007218","update-policy":"https:\/\/doi.org\/10.1371\/journal.pcbi.corrections_policy","source":"Crossref","is-referenced-by-count":45,"title":["Optimizing circadian drug infusion schedules towards personalized cancer chronotherapy"],"prefix":"10.1371","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5049-5473","authenticated-orcid":true,"given":"Roger J. W.","family":"Hill","sequence":"first","affiliation":[]},{"given":"Pasquale F.","family":"Innominato","sequence":"additional","affiliation":[]},{"given":"Francis","family":"L\u00e9vi","sequence":"additional","affiliation":[]},{"given":"Annabelle","family":"Ballesta","sequence":"additional","affiliation":[]}],"member":"340","published-online":{"date-parts":[[2020,1,27]]},"reference":[{"key":"pcbi.1007218.ref001","unstructured":"CASyM. CASyM and the road to Systems Medicine; 2015."},{"issue":"6258","key":"pcbi.1007218.ref002","first-page":"282","article-title":"Experimentation Can Enable Precision Medicine","volume":"350","author":"BR Iyengar","year":"2015","journal-title":"Science"},{"issue":"3","key":"pcbi.1007218.ref003","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/gm538","article-title":"Enabling multiscale modeling in systems medicine","volume":"6","author":"O Wolkenhauer","year":"2014","journal-title":"Genome Medicine"},{"issue":"3","key":"pcbi.1007218.ref004","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/nrc2329","article-title":"Integrative mathematical oncology","volume":"8","author":"ARA Anderson","year":"2008","journal-title":"Nature Reviews Cancer"},{"issue":"3","key":"pcbi.1007218.ref005","first-page":"239","article-title":"Personalizing oncology treatments by predicting drug efficacy, side-effects, and improved therapy: Mathematics, statistics, and their integration","volume":"6","author":"Z Agur","year":"2014","journal-title":"Wiley Interdisciplinary Reviews: Systems Biology and Medicine"},{"issue":"3","key":"pcbi.1007218.ref006","first-page":"135","article-title":"Bridging systems medicine and patient needs","volume":"4","author":"JP Boissel","year":"2015","journal-title":"CPT: Pharmacometrics and Systems Pharmacology"},{"issue":"4","key":"pcbi.1007218.ref007","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1097\/01.NURSE.0000480617.62296.d7","article-title":"The urgent need for innovation in I.V. infusion devices","volume":"46","author":"KK Giuliano","year":"2016","journal-title":"Nursing"},{"issue":"1","key":"pcbi.1007218.ref008","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1146\/annurev-med-053013-053944","article-title":"Pharmacogenetics of Cancer Drugs","volume":"66","author":"DL Hertz","year":"2015","journal-title":"Annual Review of Medicine"},{"issue":"2","key":"pcbi.1007218.ref009","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1002\/ijc.28940","article-title":"Personalised cancer medicine","volume":"137","author":"SE Jackson","year":"2015","journal-title":"International Journal of Cancer"},{"issue":"12","key":"pcbi.1007218.ref010","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1016\/j.ejca.2014.04.014","article-title":"Review of therapeutic drug monitoring of anticancer drugs part 1\u2014Cytotoxics","volume":"50","author":"A Paci","year":"2014","journal-title":"European Journal of Cancer"},{"issue":"2","key":"pcbi.1007218.ref011","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1124\/pr.116.013441","article-title":"Systems Chronotherapeutics","volume":"69","author":"A Ballesta","year":"2017","journal-title":"Pharmacological Reviews"},{"issue":"9-10","key":"pcbi.1007218.ref012","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/j.addr.2006.11.001","article-title":"Implications of circadian clocks for the rhythmic delivery of cancer therapeutics","volume":"59","author":"F L\u00e9vi","year":"2007","journal-title":"Advanced Drug Delivery Reviews"},{"issue":"5","key":"pcbi.1007218.ref013","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.molmed.2016.03.004","article-title":"Dosing-Time Makes the Poison: Circadian Regulation and Pharmacotherapy","volume":"22","author":"R Dallmann","year":"2016","journal-title":"Trends in Molecular Medicine"},{"issue":"9-10","key":"pcbi.1007218.ref014","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.addr.2010.06.002","article-title":"Chronotherapy and the molecular clock: Clinical implications in oncology","volume":"62","author":"PF Innominato","year":"2010","journal-title":"Advanced Drug Delivery Reviews"},{"issue":"November","key":"pcbi.1007218.ref015","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1146\/annurev.pharmtox.48.113006.094626","article-title":"Circadian timing in cancer treatments","volume":"50","author":"F Levi","year":"2010","journal-title":"Annual review of pharmacology and toxicology"},{"issue":"12","key":"pcbi.1007218.ref016","doi-asserted-by":"crossref","first-page":"3110","DOI":"10.1093\/annonc\/mds148","article-title":"Sex moderates circadian chemotherapy effects on survival of patients with metastatic colorectal cancer: A meta-analysis","volume":"23","author":"S Giacchetti","year":"2012","journal-title":"Annals of Oncology"},{"issue":"24","key":"pcbi.1007218.ref017","doi-asserted-by":"crossref","first-page":"7176","DOI":"10.1158\/0008-5472.CAN-13-1528","article-title":"A circadian clock transcription model for the personalization of cancer chronotherapy","volume":"73","author":"XM Li","year":"2013","journal-title":"Cancer Research"},{"issue":"suppl_5","key":"pcbi.1007218.ref018","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdx393.048","article-title":"Sex-related differences in circadian-dependent tolerance of Irinotecan (I) added to chronomodulated (chrono) 5-Fluorouracil (F), Leucovorin (L) and Oxaliplatin (O): Final results from international randomised time-finding study in patients with metast","volume":"28","author":"F Levi","year":"2017","journal-title":"Annals of Oncology"},{"issue":"1","key":"pcbi.1007218.ref019","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-016-2319-9","article-title":"Relevance of internal time and circadian robustness for cancer patients","volume":"16","author":"E Ortiz-Tudela","year":"2016","journal-title":"BMC Cancer"},{"key":"pcbi.1007218.ref020","first-page":"1","article-title":"Pharmacokinetics of Irinotecan, Oxaliplatin and 5-Fluorouracil During Hepatic Artery Chronomodulated Infusion: A Translational European OPTILIV Study","author":"F L\u00e9vi","year":"2016","journal-title":"Clinical Pharmacokinetics"},{"key":"pcbi.1007218.ref021","unstructured":"Evans LC, Society AM. Partial Differential Equations. Graduate studies in mathematics. American Mathematical Society; 1998. Available from: https:\/\/books.google.co.uk\/books?id=5Pv4LVB_m8AC."},{"issue":"4","key":"pcbi.1007218.ref022","doi-asserted-by":"crossref","first-page":"895","DOI":"10.2165\/00003495-200060040-00005","article-title":"Oxaliplatin: A review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies","volume":"60","author":"CR Culy","year":"2000","journal-title":"Drugs"},{"issue":"1","key":"pcbi.1007218.ref023","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.clpt.2004.03.008","article-title":"Lack of pharmacokinetic interaction between 5-fluorouracil and oxaliplatin","volume":"76","author":"SP Joel","year":"2004","journal-title":"Clinical Pharmacology & Therapeutics"},{"issue":"7","key":"pcbi.1007218.ref024","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1080\/07357900601063766","article-title":"A systematic review on drug interactions in oncology","volume":"24","author":"RP Riechelmann","year":"2006","journal-title":"Cancer Investigation"},{"issue":"3","key":"pcbi.1007218.ref025","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1053\/jlts.2002.31654","article-title":"Body surface area and body weight predict total liver volume in western adults","volume":"8","author":"JN Vauthey","year":"2002","journal-title":"Liver Transplantation"},{"issue":"2","key":"pcbi.1007218.ref026","first-page":"224","article-title":"Prediction of blood volume in normal human adults","volume":"51","author":"SB Nadler","year":"1962","journal-title":"Surgery"},{"issue":"1","key":"pcbi.1007218.ref027","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1152\/jappl.1966.21.1.167","article-title":"Determination of human body volume from height and weight","volume":"21","author":"J Sendroy","year":"1966","journal-title":"Journal of Applied Physiology"},{"issue":"1","key":"pcbi.1007218.ref028","first-page":"1205","article-title":"Clinical Pharmacokinetics of Oxaliplatin: A Critical Review","volume":"18","author":"MA Graham","year":"2000","journal-title":"Clinical Cancer Research"},{"issue":"4","key":"pcbi.1007218.ref029","first-page":"423","article-title":"Pharmacokinetics, Metabolism, and Excretion of Irinotecan (Cpt-11) following I. V. Infusion of [14C]Cpt-11 in Cancer Patients","volume":"28","author":"JG Slatter","year":"2000","journal-title":"Drug Metabolism and Disposition"},{"issue":"7","key":"pcbi.1007218.ref030","first-page":"13","article-title":"Biochemical and Clinical Pharmacology of 5-Fluorouracil Cellular Determinants of Sensitivity to Fluoropyrimidines","volume":"12","author":"BRL Schilsky","year":"1998","journal-title":"Oncology"},{"issue":"12","key":"pcbi.1007218.ref031","first-page":"3362","article-title":"Circadian rhythm in toxicities and tissue uptake of 1,2-diamminocyclohexane(trans-1)oxalatoplatinum(II) in mice","volume":"49","author":"NA Boughattas","year":"1989","journal-title":"Cancer Research"},{"issue":"5","key":"pcbi.1007218.ref032","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.apsb.2018.05.005","article-title":"Human carboxylesterases: a comprehensive review","volume":"8","author":"D Wang","year":"2018","journal-title":"Acta Pharmaceutica Sinica B"},{"issue":"7","key":"pcbi.1007218.ref033","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/0006-2952(96)00457-1","article-title":"Conversion of irinotecan (CPT-11) to its active metabolite, 7-ethyl-10-hydroxycamptothecin (SN-38) by human liver carboxylesterase","volume":"52","author":"LP Rivory","year":"1996","journal-title":"Biochemical Pharmacology"},{"key":"pcbi.1007218.ref034","doi-asserted-by":"crossref","first-page":"42113","DOI":"10.1038\/srep42113","article-title":"Allometric scaling in-vitro","volume":"7","author":"A Ahluwalia","year":"2017","journal-title":"Scientific Reports"},{"issue":"8","key":"pcbi.1007218.ref035","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1023\/A:1010939329562","article-title":"A physiologically based pharmacokinetic analysis of capecitabine, a triple prodrug of 5-FU, in humans: The mechanism for tumor-selective accumulation of 5-FU","volume":"18","author":"Y Tsukamoto","year":"2001","journal-title":"Pharmaceutical Research"},{"issue":"1","key":"pcbi.1007218.ref036","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1023\/A:1006379730137","article-title":"In vitro binding and partitioning of irinotecan (CPT-11) and its metabolite, SN-38, in human blood","volume":"18","author":"O Combes","year":"2000","journal-title":"Investigational New Drugs"},{"issue":"9","key":"pcbi.1007218.ref037","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pcbi.1002143","article-title":"A combined experimental and mathematical approach for molecular-based optimization of irinotecan circadian delivery","volume":"7","author":"A Ballesta","year":"2011","journal-title":"PLoS Computational Biology"},{"issue":"9","key":"pcbi.1007218.ref038","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/0731-7085(95)01548-Y","article-title":"The binding of 5-fluorouracil to native and modified human serum albumin: UV, CD, and 1H and 19F NMR investigation","volume":"13","author":"C Bertucci","year":"1995","journal-title":"Journal of pharmaceutical and biomedical analysis"},{"key":"pcbi.1007218.ref039","unstructured":"Pfizer. CAMPTOSAR (Irinotecan) HIGHLIGHTS OF PRESCRIBING INFORMATION; 2014. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/020571s048lbl.pdf."},{"issue":"19","key":"pcbi.1007218.ref040","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1016\/j.fss.2007.03.004","article-title":"On fuzzy cluster validity indices","volume":"158","author":"W Wang","year":"2007","journal-title":"Fuzzy Sets and Systems"},{"issue":"1","key":"pcbi.1007218.ref041","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s00280-018-3722-5","article-title":"Population pharmacokinetics of FOLFIRINOX: a review of studies and parameters","volume":"83","author":"L Deyme","year":"2019","journal-title":"Cancer Chemotherapy and Pharmacology"},{"issue":"November 2015","key":"pcbi.1007218.ref042","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1093\/annonc\/mdv548","article-title":"Conversion to resection of liver metastases from colorectal cancer with hepatic artery infusion of combined chemotherapy and systemic cetuximab in multicenter trial OPTILIV","volume":"27","author":"FA L\u00e9vi","year":"2016","journal-title":"Annals ofOncology"},{"issue":"7","key":"pcbi.1007218.ref043","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1038\/bjc.2017.278","article-title":"Pharmacogenetic determinants of outcomes on triplet hepatic artery infusion and intravenous cetuximab for liver metastases from colorectal cancer (European trial OPTILIV, NCT00852228)","volume":"117","author":"F L\u00e9vi","year":"2017","journal-title":"British Journal of Cancer"},{"key":"pcbi.1007218.ref044","unstructured":"Jones E, Oliphant T, Peterson P, Others. {SciPy}: Open source scientific tools for {Python}; 2001. Available from: http:\/\/www.scipy.org\/%22."},{"key":"pcbi.1007218.ref045","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jchromb.2016.02.012","article-title":"Development and validation of an UPLC-MS\/MS method for the quantification of irinotecan, SN-38 and SN-38 glucuronide in plasma, urine, feces, liver and kidney: Application to a pharmacokinetic study of irinotecan in rats","volume":"1015-1016","author":"S Basu","year":"2016","journal-title":"Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences"},{"key":"pcbi.1007218.ref046","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/812701","article-title":"Development and Validation of a Simple and Selective Analytical HPLC Method for the Quantification of Oxaliplatin","volume":"2015","author":"BN Matos","year":"2015","journal-title":"Journal of Chemistry"},{"issue":"4","key":"pcbi.1007218.ref047","doi-asserted-by":"crossref","first-page":"557","DOI":"10.35841\/biomedicalresearch.30-19-244","article-title":"Spectrophotometric determination of cisplatin, carboplatin and oxaliplatin in pure and injectable dosage forms","volume":"30","author":"M Munawar Hayat","year":"2019","journal-title":"Biomedical Research"},{"key":"pcbi.1007218.ref048","unstructured":"Sendhoff B. Covariance Matrix Adaptation Revisited\u2014the CMSA Evolution Strategy \u2013. International Conference on Parallel Problem Solving from Nature. 2008;3242(Conference Paper \u00b7 September 2008)."},{"key":"pcbi.1007218.ref049","first-page":"69","article-title":"Sobol Sensitivity Analysis: A Tool to Guide the Development and Evaluation of Systems Pharmacology Models","volume":"4","author":"Xy Zhang","year":"2015","journal-title":"CPT: pharmacometrics & systems pharmacology"},{"issue":"15","key":"pcbi.1007218.ref050","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1093\/bioinformatics\/btp358","article-title":"Structural and practical identifiability analysis of partially observed dynamical models by exploiting the profile likelihood","volume":"25","author":"A Raue","year":"2009","journal-title":"Bioinformatics"},{"issue":"5-6","key":"pcbi.1007218.ref051","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1007\/s10928-005-0078-3","article-title":"Sample Size Computations for PK \/ PD Population Models","volume":"32","author":"D Kang","year":"2005","journal-title":"Journal of Pharmacokinetics and Pharmacodynamics"},{"issue":"5","key":"pcbi.1007218.ref052","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1080\/10543401003619205","article-title":"Sample Size \/ Power Calculations for Population Pharmacodynamic Experiments Involving Repeated-Count Measurements","volume":"20","author":"K Ogungbenro","year":"2010","journal-title":"Journal of Biopharmaceutical Statistics ISSN"},{"key":"pcbi.1007218.ref053","first-page":"2825","article-title":"Scikit-learn: Machine Learning in {P}ython","volume":"12","author":"F Pedregosa","year":"2011","journal-title":"Journal of Machine Learning Research"},{"issue":"1","key":"pcbi.1007218.ref054","doi-asserted-by":"crossref","DOI":"10.20982\/tqmp.05.1.p001","article-title":"A Review of Multidimensional Scaling (MDS) and its Utility in Various Psychological Domains","volume":"5","author":"N Jaworska","year":"2009","journal-title":"Tutorials in Quantitative Methods for Psychology"}],"updated-by":[{"DOI":"10.1371\/journal.pcbi.1007218","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2020,2,6]],"date-time":"2020-02-06T00:00:00Z","timestamp":1580947200000}}],"container-title":["PLOS Computational Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pcbi.1007218","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,6]],"date-time":"2020-02-06T16:08:57Z","timestamp":1581005337000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pcbi.1007218"}},"subtitle":[],"editor":[{"given":"James","family":"Gallo","sequence":"first","affiliation":[]}],"short-title":[],"issued":{"date-parts":[[2020,1,27]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,1,27]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pcbi.1007218","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/688606","asserted-by":"object"}]},"ISSN":["1553-7358"],"issn-type":[{"value":"1553-7358","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,27]]}}}